farnesol has been researched along with oleic acid in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fushiki, T; Goto, T; Hosokawa, M; Kawada, T; Kimura, K; Matsui, N; Miyashita, K; Saito, M; Taimatsu, A; Takahashi, N; Yamamoto, T | 1 |
Kocarek, TA; Pant, A; Rondini, EA | 1 |
2 other study(ies) available for farnesol and oleic acid
Article | Year |
---|---|
Dual action of isoprenols from herbal medicines on both PPARgamma and PPARalpha in 3T3-L1 adipocytes and HepG2 hepatocytes.
Topics: 3T3 Cells; Adipocytes; Animals; Carotenoids; Cell Line; CREB-Binding Protein; Diterpenes; Dose-Response Relationship, Drug; Farnesol; Genes, Reporter; Hepatocytes; Humans; Ligands; Mice; Nuclear Proteins; Oleic Acid; Plant Preparations; Polymerase Chain Reaction; Receptors, Cytoplasmic and Nuclear; Terpenes; Trans-Activators; Transcription Factors; Transfection; Up-Regulation | 2002 |
Farnesol induces fatty acid oxidation and decreases triglyceride accumulation in steatotic HepaRG cells.
Topics: Cell Line, Tumor; Constitutive Androstane Receptor; Farnesol; Fatty Acids; Gene Expression Regulation, Enzymologic; Hepatocytes; Humans; Mitochondria, Liver; Non-alcoholic Fatty Liver Disease; Oleic Acid; Oxidation-Reduction; PPAR alpha; Receptors, Cytoplasmic and Nuclear; Triglycerides | 2019 |